← Eichor
Study identifier: NCT05933720 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Efficacy and Safety of the Regulatory Polypeptides in Patients With Peripheral Atherosclerosis.

Condition: Peripheral Arterial Occlusive Disease  ·  Sponsor: Ryazan State Medical University

PhaseNA
Planned participants120
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersNo

About this study

The study is aimed at assessing the role of the activity of markers of endothelial dysfunction (cytotoxic malonic aldehyde (MDA), angiotensin II, endothelial nitric oxide synthase (NO), endothelin-1, prostacyclin) in the systemic circulation in patients with lower extremity atherosclerotic arterial occlusive disease undergoing open reconstructive interventions.

This description comes directly from the study's public registry record.

Talk to the study team

Igor Aleksadrovich Suchkov  ·  8-903-836-24-17  ·  suchkov_med@mail.ru

Always discuss trial participation with your own doctor first.

Locations (1)

RyazanSMURyazan, RussiaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05933720